Oncology

Effectiveness of Vermilionectomy in SCC and AC of the Lower Lip Investigated

December 15, 2017

SCC was revealed accompanying AC in 14 patients in postoperative biopsy; four patients in the AC-only group had SCC in situ.

Do Pre-Op Cholesterol Levels Impact Post-Op Pain Outcomes?

December 13, 2017

The researchers observed a weak, but significant, positive correlation between total cholesterol and numeric rating scale scores on post operative days 0 and 1.

Addtion of Daratumumab to Standard Tx Assessed in Multiple Myeloma

December 13, 2017

The researchers found that the 18-month progression-free survival rate was 71.6% and 50.2% in the daratumumab and control groups, respectively, at a median follow-up of 16.5 months.

Accuracy of Artificial Intelligence Assessed in CA Diagnosis

December 12, 2017

The researchers found that the AUC of the DLS for referable diabetic retinopathy was 0.936, and sensitivity and specificity were 90.5 and 91.6%, respectively

A+AVD Versus ABVD in Advanced Hodgkin's Lymphoma

December 11, 2017

The researchers found that the two-year progression-free survival rates were 82.1 and 77.2% in the A+AVD and ABVD groups at a median follow-up of 24.9 months.

Enzalutamide Seizure Risk Factor Assessed in mCRPC

December 08, 2017

Within 4 months of enzalutamide initiation, four patients (1.1%) had at least one confirmed seizure; three additional patients (0.8%) experienced a seizure within four months following the 4-month study period.

Acupuncture May Relieve Aromatase Inhibitor-Linked Joint Pain

December 08, 2017

The researchers found that the 6-week mean BPI worst pain scores were 0.92 points lower in the true acupuncture versus sham acupuncture arm, and 0.96 points lower in the true acupuncture versus waitlist control arm.

Kisqali Shows Promise in Premenopausal Breast CA Population

By December 08, 2017

Results found a median PFS of 23.8 months (95% CI: 19.2 months-not reached) for the Kisqali group compared to 13.0 months (95% CI: 11.0-16.4 months) for tamoxifen or an aromatase inhibitor plus goserelin (HR=0.553; 95% CI: 0.441-0.694; P<0.0001).

'No Rationale' for Extended Anastrozole Tx in HR&#43; Early Breast CA, Study Finds

December 08, 2017

"There is simply no rationale to keep most patients on extended aromatase inhibitor for longer than two years," said lead author Michael Gnant in a statement.

Hormonal Contraceptives and Breast Cancer: What's the Link?

December 07, 2017

Findings from nationwide study in Denmark show small absolute increase in breast cancer risk

Ribociclib Addition Assessed for PFS in HR&#43; HER2&#8722; Advanced Breast CA

December 07, 2017

Researchers conducted a randomized phase III trial assessing ribociclib + tamoxifen/non-steroidal aromatase inhibitor and goserelin in pre- and peri-menopausal women.

Avastin Gains Full FDA Approval for Recurrent Glioblastoma

By December 06, 2017

The conversion from provisional to full approval was based on totality of evidence of Avastin in glioblastoma.

Cancer Drug Linked to Drastic Depletion of HIV Reservoirs

December 04, 2017

Case report describes smoker with HIV infection receiving nivolumab for non-small-cell lung cancer

FDA Approves Second Biosimilar for the Treatment of Cancer

By December 01, 2017

Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for the treatment of cancer.

Can Co-Testing Support Longer Cervical Cancer Screening Intervals?

November 28, 2017

Regardless of the cytology result, 5-year ≥CIN3 risks for an HPV-negative co-test nearly matched the performance of a negative co-test for each successive round of screening (0.114, 0.061, and 0041%, respectively).

Coffee Consumption and Health Outcomes: An Umbrella Review of the Evidence

November 27, 2017

After adequate adjustment for smoking, harmful associations were mainly nullified, except in pregnancy, where there were correlations for high versus low/no consumption with low birth weight, preterm birth in the first and second trimester, and pregnancy loss.

Patidegib Gets Breakthrough and Orphan Designation for Gorlin Syndrome

By November 20, 2017

Gorlin Syndrome is a rare, genetic disease characterized by mutations in the tumor suppressor gene encoding Patched1.

Sutent Approved for Patients at High Risk of Recurrent RCC

By November 17, 2017

Sutent was first approved in 2006 for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma.

Erlotinib Overdose May Lead to Rapid Onset of Ocular Toxicity

November 17, 2017

Findings in case study of man being treated for non-small-cell lung cancer

Survival With Combo Bevacizumab + Lomustine Tx Examined in Glioblastoma

November 17, 2017

However, locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group.

Gazyva OK'd for Previously Untreated Advanced Follicular Lymphoma

By November 16, 2017

The approval is based on results from the Phase 3 GALLIUM study.

Faslodex Approved as Combo Tx for Advanced Breast Cancer

By November 15, 2017

The FDA approval is based on data from the Phase 3 MONARCH 2 trial, which met the study's primary endpoint of PFS.

FDA Approves InSure One to Aid in Detecting Lower GI Bleeding

By November 13, 2017

The InSure ONE requires a sample of water from the toilet bowl, after the stool surface has been brushed to release any blood.

Cinvanti Approved for Chemotherapy-Induced Nausea and Vomiting

By November 10, 2017

The approval of Cinvanti was supported by Phase 2 bioequivalence data of Cinvanti and Emend IV (fosaprepitant dimeglumine; Merck), where patients treated with Cinvanti experienced fewer adverse events vs. patients treated with Emend IV, including substantially fewer infusion-site reactions.

Sprycel Approved for Pediatric Patients With Ph+ CML in Chronic Phase

By November 10, 2017

Second-generation tyrosine kinase inhibitor approved for children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Opioid Rx Patterns Assessed Post-Hysterectomy

November 10, 2017

Patients reported using about half of the opioids prescribed, with a median excess of 110 oral morphine equivalents.

Breast Cancer Recurrences Steady After Therapy Cessation

November 10, 2017

The risk of distant recurrence was 13, 20, and 34%, respectively, among patients with stage T1 disease with no nodal involvement (T1N0), with one to three nodes involved (T1N1-3), and with 4 to 9 nodes involved (T1N4-9).

Adcetris Approved for Primary Cutaneous Anaplastic Large Cell Lymphoma

By November 09, 2017

Approval was based on a Phase 3, randomized, open-label, multicenter clinical trial (ALCANZA) of brentuximab vedotin in patients with mycosis fungoides or pcALCL who had previously received one prior systemic therapy and required systemic treatment.

IUD Use and Cervical Cancer Risk: What's the Link?

By November 09, 2017

The data showed women who used IUD had a lower occurrence of cervical cancer (odds ratio [OR] 0.64, 95% CI: 0.53-0.77).

Adipocytes May Clear Daunorubicin, Contribute to Poorer Survival Outcomes

November 09, 2017

The researchers found that adipocytes absorbed and metabolized daunorubicin to daunorubicinol, which reduced its anti-leukemia effect. Daunorubicin conversion to daunorubicinol was confirmed in vivo in murine studies.